Restructuring & Reorganization
Selected Transactions
 
Stiefel Header
Date
Closed April 2009

Company Description
Stiefel Laboratories Inc. was an American-based private company with a 160-year heritage in dermatology products, an expansive R&D pipeline, and more than 275 brands sold in nearly 100 countries.

Situation Overview
Advised Stiefel on the sale of the company to GlaxoSmithKline plc (GSK) after conducting a highly competitive auction. Total transaction value was $3.6 billion.

Transaction Summary
Stiefel’s objective was to be maximize value for its shareholders.  Stiefel and Blackstone determined that a sale process may be able to create superior shareholder value and pursued a targeted auction including the most viable strategic parties.  GSK’s acquisition of Stiefel creates a world-leading specialist dermatology business under the leadership of key Stiefel senior management.

Legal Transparency & Disclosure 金融商品取引法第37条に定める事項の表示 Site Map Contact Us Careers © The Blackstone Group L.P.,   2013–2014. All rights reserved. English Chinese Japanese